https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&zc=1&src=https://www.marketbeat.com/logos/allergan-inc-logo.gif

ETRADE Capital Management LLC Sells 1,830 Shares of Allergan plc (NYSE:AGN)

by

ETRADE Capital Management LLC cut its position in shares of Allergan plc (NYSE:AGN) by 36.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,173 shares of the company’s stock after selling 1,830 shares during the quarter. ETRADE Capital Management LLC’s holdings in Allergan were worth $562,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Wealth Quarterback LLC acquired a new stake in shares of Allergan during the 4th quarter valued at about $25,000. Golden State Wealth Management LLC bought a new stake in Allergan during the first quarter worth about $25,000. WASHINGTON TRUST Co bought a new position in Allergan in the 1st quarter valued at $25,000. Paragon Capital Management LLC bought a new stake in Allergan during the 1st quarter worth about $30,000. Finally, Ellevest Inc. raised its position in Allergan by 233.3% in the 1st quarter. Ellevest Inc. now owns 180 shares of the company’s stock worth $32,000 after purchasing an additional 126 shares during the last quarter. Hedge funds and other institutional investors own 83.91% of the company’s stock.

A number of equities analysts have issued reports on AGN shares. ValuEngine upgraded Allergan from a “sell” rating to a “hold” rating in a report on Tuesday, March 24th. Cfra lowered Allergan from a “buy” rating to a “hold” rating in a report on Wednesday, March 25th. Finally, SunTrust Banks cut Allergan from a “buy” rating to a “hold” rating and boosted their target price for the company from $191.00 to $193.00 in a research note on Tuesday, April 21st. Fourteen investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $183.73.

Shares of AGN stock opened at $193.02 on Monday. Allergan plc has a one year low of $114.27 and a one year high of $202.21. The business’s 50 day simple moving average is $185.22 and its 200 day simple moving average is $187.00. The stock has a market capitalization of $63.50 billion, a PE ratio of -12.07, a PEG ratio of 1.63 and a beta of 1.20. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.01 and a quick ratio of 0.84.

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 15th. Investors of record on Thursday, April 16th will be paid a dividend of $0.74 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.96 annualized dividend and a yield of 1.53%. Allergan’s dividend payout ratio is currently 16.78%.

Allergan Company Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Featured Story: What does the Producer Price Index (PPI) tell investors?

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&Symbol=AGN